The flu shot you got last year is a piece of 1940s technology dressed up with a modern label. It's grown in chicken eggs over about six months, and by the time it reaches your arm, the strains inside it are educated guesses made half a year earlier. On August 5, the FDA approved something built on entirely different plumbing.

Let's get the number on the table first: 26.6%. That's how much better Moderna's new mRNA flu vaccine, mFlusiva, performed against confirmed influenza compared to a standard-dose shot in adults 50 and older — the relative vaccine efficacy from a 40,000-plus person Phase 3 trial (CIDRAP). It's the first mRNA-based flu vaccine ever cleared for sale, anywhere.

And it almost didn't get looked at. Six months ago, the same FDA refused to even open Moderna's file. This is the story of a shot that had to survive its own regulator before it could face a virus.

🧠 Why This Matters

Every seasonal flu vaccine you've ever received works the same slow way. Manufacturers pick the strains in late winter, brew them in eggs through spring and summer, and ship whatever they committed to months earlier. When the guess is good, the shot works. When a strain drifts after the recipe is locked, effectiveness can crater — some seasons dip below 40%.

mRNA changes the production math. Instead of growing virus, you print genetic instructions that tell your cells to build the flu protein themselves. That's the same trick that let Moderna and Pfizer go from a COVID genome to a shot in under a year. Applied to flu, it means the recipe can be updated closer to the season and swapped faster when a strain shifts. mFlusiva is the first proof that the approach clears the regulatory bar for influenza — not just a pandemic emergency.

For Moderna, the stakes are corporate survival, not just science. COVID vaccine sales have fallen off a cliff since 2022, and the company has spent three years hunting for a second product that sells. A flu franchise for America's roughly 70 million seniors is the most obvious candidate on the board.

📊 Deep Dive

The efficacy data came from a randomized, observer-blind trial that pitted a single dose of mFlusiva against a licensed standard-dose comparator. The headline results, confirmed across independent reporting:

  • Overall efficacy (50+): 26.6% relative vaccine efficacy, with a 95% confidence interval of 16.7% to 35.4% (Contagion Live)
  • Adults 65+: 27.4% relative efficacy — the group that lands in the hospital most
  • By strain: 29.6% against A/H1N1, 22.2% against A/H3N2, 29.1% against B/Victoria
  • Raw infection rate: 2.0% of mRNA recipients caught the flu versus 2.8% on the standard shot
  • Trial scale: more than 40,000 adults across 301 sites in 11 countries

Flu-related healthcare visits told an even better story: a 33.7% relative reduction, with 80 mRNA recipients seeking care versus 120 in the comparator group (CIDRAP). The FDA gave traditional approval for ages 50 to 64 and accelerated approval for 65 and up, the latter leaning on a separate 2,992-person U.S. study with confirmatory trials still required after launch (Becker's).

"Flu remains a significant public health challenge, and mFlusiva provides an important new option for America's seniors." — Stéphane Bancel, CEO, Moderna

⚠️ The Catch

Start with the number itself. A 26.6% relative improvement is not the same as a shot that stops the flu cold. It means mFlusiva prevented roughly a quarter more infections than an already-modest standard vaccine. In absolute terms, that's the gap between a 2.8% and a 2.0% infection rate. Real, measurable, but not the leap the word "breakthrough" tends to promise.

Then there's how it got here. In February 2026, FDA official Vinay Prasad issued a rare "refuse-to-file" notice, blocking the agency from even reviewing Moderna's application (STAT). Moderna went public with the dispute, and on February 18 the FDA reversed itself. Prasad left the agency in April. The approval landed six months later — a reminder that mRNA vaccines are now moving through a regulatory environment where the science isn't always the deciding factor.

The vaccine cleared a 40,000-person trial in eleven countries. Getting the FDA to open the envelope took a public fight.

🎯 What Happens Next

Moderna says mFlusiva will reach select retailers in the coming weeks, in time for the 2026–2027 respiratory-virus season (Becker's). Regulators in Europe, Canada, and Australia are reviewing their own applications.

The bigger prize is the combination shot. Moderna has been developing a single jab that covers both flu and COVID, and the flu component was the piece the FDA had flagged for more data (Healthcare Dive). With mFlusiva approved on its own, the path to resubmitting that combo — one appointment, one needle, two viruses — is suddenly clearer.

🧩 Bigger Picture

Flu kills tens of thousands of Americans in a bad year, most of them elderly, and the vaccines meant to stop it have been running on decades-old chemistry. A platform that updates in weeks instead of months matters most for exactly the scenario nobody wants: a fast-drifting strain, or the next pandemic, where the egg timeline is the enemy.

mFlusiva doesn't prove mRNA is dramatically better at flu — a 27% edge is an improvement, not a revolution. What it proves is that the manufacturing model works for a routine, non-emergency disease, and that regulators will license it. That's the door Moderna actually needed open. Whether the technology lives up to its speed advantage depends on the seasons ahead, when a badly matched strain finally tests whether "update it faster" is more than a slide in a pitch deck.

The egg-based shot took eighty years to get a serious rival. The rival's first real test is the flu season that starts in a few weeks.

Sources